CL2014002556A1 - Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. - Google Patents

Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.

Info

Publication number: CL2014002556A1
Authority: CL; Chile
Prior art keywords: indanyloxidihydrobenzofuranylacetic; obesity; diabetes; diseases; acids
Prior art date: 2012-03-26

Application number

CL2014002556A

Other languages

English (en)

Inventor

Holger Wagner

Frank Himmelsbach

Elke Langkopf

Matthias Eckhardt

Sara Frattini

Dieter Hamprecht

Stefan Petersw

Iain Lingard

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-26

Filing date

2014-09-25

Publication date

2015-02-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-25 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-02-13 Publication of CL2014002556A1 publication Critical patent/CL2014002556A1/es

Links

206010022489 Insulin Resistance Diseases 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
239000002253 acid Substances 0.000 title 1
150000007513 acids Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2014002556A 2012-03-26 2014-09-25 Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. CL2014002556A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12161240		2012-03-26

Publications (1)

Publication Number	Publication Date
CL2014002556A1 true CL2014002556A1 (es)	2015-02-13

Family

ID=48013980

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002556A CL2014002556A1 (es)	2012-03-26	2014-09-25	Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.

Country Status (23)

Country	Link
US (1)	US8642585B2 (es)
EP (2)	EP2831053B1 (es)
JP (2)	JP6131492B2 (es)
KR (1)	KR20140139088A (es)
CN (1)	CN104321319A (es)
AP (1)	AP2014007903A0 (es)
AR (1)	AR090493A1 (es)
AU (1)	AU2013241926A1 (es)
CA (1)	CA2868474A1 (es)
CL (1)	CL2014002556A1 (es)
CO (1)	CO7091175A2 (es)
EA (1)	EA201401053A1 (es)
EC (1)	ECSP14023238A (es)
HK (1)	HK1201260A1 (es)
MA (1)	MA20150065A1 (es)
MX (1)	MX2014011465A (es)
PE (1)	PE20142019A1 (es)
PH (1)	PH12014502141A1 (es)
SG (1)	SG11201405713UA (es)
TN (1)	TN2014000398A1 (es)
TW (1)	TW201400466A (es)
UY (1)	UY34704A (es)
WO (2)	WO2013144098A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR084050A1 (es) *	2010-12-01	2013-04-17	Boehringer Ingelheim Int	Acidos indaniloxidihidrobenzofuranilaceticos
US8642585B2 (en) *	2012-03-26	2014-02-04	Boehringer Ingelheim International Gmbh	Indanyloxydihydrobenzofuranylacetic acids
CN105473595A (zh) *	2013-08-23	2016-04-06	福建海西新药创制有限公司	治疗糖尿病的羧酸化合物
IN2013MU03577A (es)	2013-11-14	2015-07-31	Cadila Healthcare Ltd
EP3076959B1 (en)	2013-12-04	2018-07-04	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
EP3102198B1 (en)	2014-02-06	2020-08-26	Merck Sharp & Dohme Corp.	Antidiabetic compounds
WO2016022446A1 (en) *	2014-08-08	2016-02-11	Merck Sharp & Dohme Corp.	[5,6]-fused bicyclic antidiabetic compounds
US20180354962A1 (en) *	2015-09-09	2018-12-13	Boehringer Ingelheim International Gmbh	[{[2,3-Dihydro-1H-inden-1-yl]amino}-2H,3H-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
US10125101B2 (en)	2016-11-28	2018-11-13	Boehringer Ingelheim International Gmbh	Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7050792B2 (ja)	2017-01-26	2022-04-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
US10913720B2 (en)	2017-01-26	2021-02-09	Boehringer Ingelheim International Gmbh	Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3573959B1 (en)	2017-01-26	2021-07-28	Boehringer Ingelheim International GmbH	Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110177773B (zh)	2017-01-26	2023-08-25	勃林格殷格翰国际有限公司	苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
CN110214135B (zh)	2017-01-26	2023-02-21	勃林格殷格翰国际有限公司	茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途
US10550127B1 (en)	2017-02-08	2020-02-04	Boehringer Ingelheim International Gmbh	Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
JPWO2018181847A1 (ja) *	2017-03-31	2020-03-05	武田薬品工業株式会社	芳香環化合物
BR102018007822A2 (pt)	2017-04-20	2018-11-06	Gilead Sciences, Inc.	composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN111479795A (zh) *	2017-12-04	2020-07-31	巴斯夫欧洲公司	制备环脂族或芳脂族二醇的醚的方法
WO2019149959A1 (en) *	2018-02-05	2019-08-08	Glaxosmithkline Intellectual Property Development Limited	Ghrelin o-acyltransferase inhibitors
TWI707849B (zh)	2018-02-13	2020-10-21	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
US12083118B2 (en)	2018-03-29	2024-09-10	Arbutus Biopharma Corporation	Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
KR102591947B1 (ko)	2018-04-19	2023-10-25	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
EP3820572B1 (en)	2018-07-13	2023-08-16	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
US20210236476A1 (en) *	2018-08-29	2021-08-05	Chemocentryx, Inc.	Methods of treating cancer with small molecule pd-l1 inhibitors
TW202028183A (zh) *	2018-10-10	2020-08-01	大陸商江蘇豪森藥業集團有限公司	含氮雜芳類衍生物調節劑、其製備方法和應用
US11236085B2 (en)	2018-10-24	2022-02-01	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
JP2022552655A (ja)	2019-10-07	2022-12-19	キャリーオペ，インク．	Ｇｐｒ１１９アゴニスト
IL295825A (en)	2020-02-28	2022-10-01	Kallyope Inc	gpr40 agonists
WO2021236617A1 (en)	2020-05-19	2021-11-25	Kallyope, Inc.	Ampk activators
CA3183575A1 (en)	2020-06-26	2021-12-30	Iyassu Sebhat	Ampk activators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4594611B2 (ja) *	2002-11-08	2010-12-08	武田薬品工業株式会社	受容体機能調節剤
AU2003277576A1 (en) *	2002-11-08	2004-06-07	Takeda Pharmaceutical Company Limited	Receptor function controlling agent
CN1735408A (zh) *	2002-11-08	2006-02-15	武田药品工业株式会社	受体机能调节剂
JP4805552B2 (ja) *	2003-05-30	2011-11-02	武田薬品工業株式会社	縮合環化合物
EP1630152A4 (en)	2003-05-30	2009-09-23	Takeda Pharmaceutical	CONDENSED CYCLIC COMPOUND
EP2006271A4 (en)	2006-03-30	2011-08-10	Asahi Kasei Pharma Corp	SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF
BRPI0713378A8 (pt) *	2006-06-27	2018-01-02	Takeda Pharmaceutical	composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
NZ588983A (en)	2008-06-25	2011-11-25	Daiichi Sankyo Co Ltd	Carboxylic acid compound
AU2009303475B2 (en)	2008-10-15	2012-09-13	Amgen Inc.	Spirocyclic GPR40 modulators
WO2010143733A1 (en)	2009-06-09	2010-12-16	Takeda Pharmaceutical Company Limited	Novel fused cyclic compound and use thereof
TW201643169A (zh) *	2010-07-09	2016-12-16	艾伯維股份有限公司	作為s1p調節劑的螺-哌啶衍生物
AR084050A1 (es)	2010-12-01	2013-04-17	Boehringer Ingelheim Int	Acidos indaniloxidihidrobenzofuranilaceticos
US8642585B2 (en) *	2012-03-26	2014-02-04	Boehringer Ingelheim International Gmbh	Indanyloxydihydrobenzofuranylacetic acids

2013
- 2013-03-14 US US13/803,237 patent/US8642585B2/en active Active
- 2013-03-22 UY UY0001034704A patent/UY34704A/es unknown
- 2013-03-25 SG SG11201405713UA patent/SG11201405713UA/en unknown
- 2013-03-25 AU AU2013241926A patent/AU2013241926A1/en not_active Abandoned
- 2013-03-25 HK HK15101722.6A patent/HK1201260A1/xx unknown
- 2013-03-25 CN CN201380026597.0A patent/CN104321319A/zh active Pending
- 2013-03-25 JP JP2015502285A patent/JP6131492B2/ja not_active Expired - Fee Related
- 2013-03-25 TW TW102110560A patent/TW201400466A/zh unknown
- 2013-03-25 KR KR20147030011A patent/KR20140139088A/ko not_active Withdrawn
- 2013-03-25 JP JP2015502284A patent/JP6040486B2/ja active Active
- 2013-03-25 WO PCT/EP2013/056313 patent/WO2013144098A1/en not_active Ceased
- 2013-03-25 PE PE2014001462A patent/PE20142019A1/es not_active Application Discontinuation
- 2013-03-25 EP EP13724175.8A patent/EP2831053B1/en not_active Not-in-force
- 2013-03-25 WO PCT/EP2013/056312 patent/WO2013144097A1/en not_active Ceased
- 2013-03-25 AR ARP130100969A patent/AR090493A1/es unknown
- 2013-03-25 CA CA2868474A patent/CA2868474A1/en not_active Abandoned
- 2013-03-25 AP AP2014007903A patent/AP2014007903A0/xx unknown
- 2013-03-25 EP EP13712760.1A patent/EP2831064B1/en active Active
- 2013-03-25 EA EA201401053A patent/EA201401053A1/ru unknown
- 2013-03-25 MX MX2014011465A patent/MX2014011465A/es unknown
- 2013-03-25 MA MA37429A patent/MA20150065A1/fr unknown
2014
- 2014-09-22 TN TNP2014000398A patent/TN2014000398A1/fr unknown
- 2014-09-25 PH PH12014502141A patent/PH12014502141A1/en unknown
- 2014-09-25 CL CL2014002556A patent/CL2014002556A1/es unknown
- 2014-09-26 CO CO14213969A patent/CO7091175A2/es unknown
- 2014-10-17 EC ECIEPI201423238A patent/ECSP14023238A/es unknown

Also Published As

Publication number	Publication date
US8642585B2 (en)	2014-02-04
EP2831064B1 (en)	2016-02-17
JP2015511613A (ja)	2015-04-20
EP2831064A1 (en)	2015-02-04
AR090493A1 (es)	2014-11-19
US20130252937A1 (en)	2013-09-26
PE20142019A1 (es)	2014-12-18
CN104321319A (zh)	2015-01-28
PH12014502141A1 (en)	2014-12-01
MX2014011465A (es)	2015-01-12
WO2013144098A1 (en)	2013-10-03
CA2868474A1 (en)	2013-10-03
JP2015511612A (ja)	2015-04-20
UY34704A (es)	2013-09-30
JP6131492B2 (ja)	2017-05-24
TW201400466A (zh)	2014-01-01
AP2014007903A0 (en)	2014-08-31
MA20150065A1 (fr)	2015-02-27
KR20140139088A (ko)	2014-12-04
HK1201260A1 (en)	2015-08-28
EP2831053B1 (en)	2016-06-22
JP6040486B2 (ja)	2016-12-07
CO7091175A2 (es)	2014-10-21
AU2013241926A1 (en)	2014-09-18
TN2014000398A1 (en)	2015-12-21
EP2831053A1 (en)	2015-02-04
ECSP14023238A (es)	2015-09-30
WO2013144097A1 (en)	2013-10-03
SG11201405713UA (en)	2014-10-30
EA201401053A1 (ru)	2015-04-30

Publication	Publication Date	Title
CL2014002556A1 (es)	2015-02-13	Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
AR092925A1 (es)	2015-05-06	Derivados de exendina-4 como agonistas duales de glp1 / glucagon
CL2013002053A1 (es)	2013-11-29	Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2008001125A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2008001126A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
AR099912A1 (es)	2016-08-31	Derivados de exendina-4 como agonistas dobles de glp1 / gip o triples de glp1 / gip / glucagon
CL2014003421A1 (es)	2015-05-22	Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2009000173A1 (es)	2010-02-12	Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
CL2014000458A1 (es)	2014-09-05	Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades.
AR098738A1 (es)	2016-06-08	Análogos del péptido exendina-4 no acilados
UY34859A (es)	2014-01-31	Análogos peptídicos de la exendina 4.
UY32094A (es)	2010-04-30	Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso.
LT2916860T (lt)	2020-07-10	Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
CL2008002111A1 (es)	2008-10-24	Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
HUE061596T2 (hu)	2023-07-28	Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
CL2013002414A1 (es)	2014-01-24	Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
CL2014001994A1 (es)	2014-11-03	Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CL2013001964A1 (es)	2013-11-29	Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras.
CL2008001994A1 (es)	2008-09-22	Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2015001699A1 (es)	2015-10-30	Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
GT200900230A (es)	2011-11-29	4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
EP2718317A4 (en)	2015-04-08	GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
CL2015001537A1 (es)	2015-10-23	Compuestos derivados de piridin-2-amidas agonistas cb2; proceso de sintesis; composicion farmaceutica; uso en el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
CL2015001318A1 (es)	2015-10-02	Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.